Survey of Ophthalmology
Volume 46, Issue 1 , Pages 25-34 , July 2001

Clostridium botulinum and the Ophthalmologist: A Review of Botulism, Including Biological Warfare Ramifications of Botulinum Toxin

  • James G. Caya, MD

      Affiliations

    • Corresponding Author InformationReprint address: James G. Caya, MD, Dept. of Pathology and Laboratory Medicine, University of Wisconsin Hospital & Clinics, Room B4/257 CSC, 600 Highland Avenue, Madison, WI 53792

References 

  1. Angulo FJ, Getz J, Taylor JP, et al.  A large outbreak of botulism (the hazardous baked potato). J Infect Dis. 1998;178:172–177
  2. Arnon SS, Midura TF, Clay SA, et al.  Infant botulism. Epidemiological, clinical, and laboratory aspects. JAMA. 1977;237:1946–1951
  3. Aureli P, Fenicia L, Ferrini AM, et al.  Wound botulism (clinical and microbiological findings of an Italian case). Eur J Epidemiol. 1992;8:750–752
  4. Averbuch-Heller L, von Maydell RD, Poonyathalang A, et al.  Inverse Argyll Robertson pupil in botulism (late central manifestation). Neuro-ophthalmol. 1996;16:351–354
  5. Bakheit AMO, Ward CD, McLellan DL. Generalized botulism-like syndrome after intramuscular injections of botulism toxin Type A (a report of two cases). J Neurol Neurosurg Psychiatry. 1997;62:198
  6. Ball AP, Hopkinson RB, Farrell ID, et al.  Human botulism caused by C. botulinum type E (the Birmingham outbreak). Q J Med. 1979;48:473–491
  7. Bhatia KP, Munchau A, Thompson PD, et al.  Generalised muscular weakness after botulinum toxin injections for dystonia (a report of three cases). J Neurol Neurosurg Psychiatry. 1999;67:90–93
  8. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980;69:567–570
  9. Brin MF. Botulinum toxin (chemistry, pharmacology, toxicity, and immunology). Muscle Nerve. 1997;20(Suppl 6):S146–S168
  10. Centers for Disease Control . Wound botulism associated with parenteral cocaine abuse—New York City. MMWR. 1982;31:87–88
  11. Centers for Disease Control . Botulism—U.S., 1978. MMWR. 1979;28:73–75
  12. Centers for Disease Control and Prevention . Botulism in the U.S. 1899–1996 (Handbook for Epidemiologists, Clinicians and Laboratory Workers). Atlanta, GA: CDC; 1998;
  13. Chaudhry R, Dhawan B, Kumar D, et al.  Outbreak of suspected Clostridium butyricum botulism in India. Emerg Infect Dis. 1998;4:506–507[letter]
  14. Cherington M, Laghmari M, Karmane A, et al.  Clinical spectrum of botulism. Muscle Nerve. 1998;21:701–710
  15. Cherington M. Electrophysiologic methods as an aid in diagnosis of botulism (a review). Muscle Nerve. 1982;5:S28–S29
  16. Cherington M. Botulism. Ten-year experience. Arch Neurol. 1974;30:432–437
  17. Cherington M, Ginsburg S. Wound botulism. Arch Surg. 1975;110:436–438
  18. Cherington M. Treatment of botulism and wound botulism. In:  Balows A,  Dehaan RM,  Dowell VR,  Guze LB editor. Anaerobic Bacteria (Role in Disease). Springfield, IL: CC Thomas Co; 1974;p. 287–294
  19. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM. Biological warfare. A historical perspective. JAMA. 1997;278:412–417[see comments]
  20. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In:  Jankovic J,  Hallett M editor. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker; 1994;p. 3–13
  21. Committee on Infectious Diseases of the American Academy of Pediatrics: in 1997 Red Book. Elk Grove Village, IL, American Academy of Pediatrics, 1997, 24th ed, pp 174–6
  22. Crane JK. Preformed bacterial toxins. Clin Lab Med. 1999;19:583–599
  23. Critchley EM, Mitchell JD. Human botulism. Br J Hosp Med. 1990;43:290–292
  24. Critchley EMR, Hayes PJ, Isaacs PET. Outbreak of botulism in north-west England and Wales, June, 1989. Lancet. 1989;7:849–853
  25. Danzig R, Berkowsky PB. Why should we be concerned about biological warfare?. JAMA. 1997;278:431–432
  26. Das Gupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline Type A toxin. In:  Jankovic J,  Hallett M editor. Therapy with Botulinum Toxin. New York: Marcel Dekker; 1994;p. 15–39
  27. Davis JB, Mattman LH. C. botulinum in a fatal wound infection. JAMA. 1951;146:646–648
  28. Demarchi J, Mourgues C, Orio J, Prevot AR. Existence du botulisme humain de Type D. Bull Acad Natl Med Paris. 1958;142:580–582
  29. Dolman CE, Iida H. Type E botulism (its epidemiology, prevention and specific treatment). Can J Public Health. 1963;54:293–308
  30. Dolman CE, Murakami L. C. botulinum Type F with recent observations on other types. J Infect Dis. 1961;109:107–128
  31. Donadio JA, Gangarosa EJ, Faich GA. Diagnosis and treatment of botulism. J Infect Dis. 1971;124:108–112
  32. Dowell VR, McCroskey LM, Hatheway CL, et al.  Coproexamination for botulinal toxin and C. botulinum. A new procedure for laboratory diagnosis of botulism. JAMA. 1977;238:1829–1832
  33. Dunbar EM. Botulism. J Infect. 1990;20:1–3[published erratum appears in J Infect 1990 May;20(3):273]
  34. Edell TA, Sullivan CP, Osborn KM, et al.  Wound botulism associated with a positive tensilon test. West J Med. 1983;139:218–219
  35. Edwards RC, Butt FYS, Bonacci CA, Kendall KA. Wound botulism (a clinical experience). Otolaryngol Head Neck Surg. 1997;117(Suppl):S214–S218
  36. Ehrenreich H, Garner CG, Witt TN. Complete bilateral internal ophthalmoplegia as sole clinical sign of botulism (confirmation of diagnosis by single fibre electromyography). J Neurol. 1989;236:243–245
  37. Eisenberg MS, Bender TR. Botulism in Alaska, 1947 through 1974. Early detection of cases and investigation of outbreaks as a means of reducing mortality. JAMA. 1976;235:35–38
  38. Erbguth FJ. Botulinum toxin, a historical note. Lancet. 1998;351:1320
  39. Flacks L. Botulism in New Zealand. NZ Med J. 1985;98:892–893
  40. Franz DR, Jahrling PB, Friedlander AM, et al.  Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399–411
  41. Fred HL. Case in point. Wound botulism. Hosp Pract (Off Ed). 1994;29:39;[see comments]
  42. Friedman DI, Fortanasce VN, Sadun AA. Tonic pupils as a result of botulism. Am J Ophthalmol. 1990;109:236–237
  43. Fullerton P, Gogna NK, Stoddart R. Wound botulism. Med J Aust. 1980;1:662–663
  44. Gangarosa EJ, Donadio JA, Armstrong RW, et al.  Botulism in the U.S., 1899-1969. Am J Epidemiol. 1971;93:93–101
  45. Gill DM. Bacterial toxins (a table of lethal amounts). Microbiol Rev. 1982;46:86–94
  46. Goode GB, Shearn DL. Botulism (a case with associated sensory abnormalities). Arch Neurol. 1982;39:55
  47. Green J, Spear H, Brinson RR. Human botulism (type F)—a rare type. Am J Med. 1983;75:893–895
  48. Griffin PM, Hatheway CL, Rosenbaum RB, Sokolow R. Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohns disease. J Infect Dis. 1997;175:633–637
  49. Hall JD, McCroskey LM, Pincomb BJ, Hatheway CL. Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol. 1985;21:654–655
  50. Hambleton P. C. botulinum toxins (a general review of involvement in disease, structure, mode of action and preparation for clinical use). J Neurol. 1992;239:16–20
  51. Hampson CR. A case of probable botulism due to wound infection. J Bacteriol. 1951;61:647
  52. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies (correlation with clinical response). Neurology. 1998;50:1624–1629
  53. Hatheway CL. Botulism (the present status of the disease). Curr Top Microbiol Immunol. 1995;195:55–75
  54. Hatheway CL. C. botulinum. In:  Gorbach SL editors. Infectious Diseases. Philadelphia, PA: WB Saunders Co; 1998;p. 1919–1925ed 2
  55. Hatheway CL, Dang C. Immunogenicity of the neurotoxins of C. botulinum. In:  Jankovic J,  Hallett M editor. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker; 1994;p. 93–107
  56. Hedges TR 3d, Jones A, Stark L, Hoyt WF . Botulin ophthalmoplegia. Clinical and oculographic observations. Arch Ophthalmol. 1983;101:211–213
  57. Hikes DC, Manoli A. Wound botulism. J Trauma. 1981;21:68–71
  58. Holloway HC, Norwood AE, Fullerton CS, et al.  The threat of biological weapons. Prophylaxis and mitigation of psychological and social consequences. JAMA. 1997;278:425–427
  59. Horowitz BZ, Swensen E, Marquardt K. Wound botulism associated with black tar heroin. JAMA. 1998;280:1479–1480[letter; comment]
  60. Hoyos C, Romero J, Solari J, Garcia D: [Botulism: the first epidemic outbreak in Peru]. Rev Gastroenterol Peru 10:75–9, 1990
  61. Hughes JM, Blumenthal JR, Merson MH, et al.  Clinical features of types A and B food-borne botulism. Ann Intern Med. 1981;95:442–445
  62. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324:1186–1194
  63. Jedelhauser P: [Botulism—observations on its course with emphasis on ophthalmologic symptoms]. Klin Monatsbl Augenheilkd 186:18–24, 1985
  64. Jenzer G, Mumenthaler M, Ludin HP, Robert F. Autonomic dysfunction in botulism B (a clinical report). Neurology. 1975;25:150–153
  65. de Jesus PV, Slater R, Spitz LK, Penn AS. Neuromuscular physiology of wound botulism. Arch Neurol. 1973;29:425–431
  66. Koenig MG, Drutz DJ, Mushlin AI, et al.  Type B botulism in man. Am J Med. 1967;42:208–219
  67. Koenig MG, Spickard A, Cardella MA, Rogers DE. Clinical and laboratory observations on Type E botulism in man. Medicine. 1964;43:517–545
  68. Kudrow DB, Henry DA, Haake DA, et al.  Botulism associated with C. botulinum sinusitis after intranasal cocaine abuse. Ann Intern Med. 1988;109:984–985
  69. Lacy DB, Tepp W, Cohen AC, et al.  Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998;5:898–902
  70. Lamagnere J-P, Maupas P, Breteau M, et al.  Le botulisme. Sem Hop Paris. 1973;49:1077–1085
  71. Laroche L, Ollat H, Mignot B, et al.  [Ocular manifestations of botulism. Apropos of. 1984;3(cases]. Bull Soc Ophtalmol Fr 84):555–558
  72. Lecour H, Ramos H, Almeida B, Barbosa R. Food-borne botulism. A review of. 1988;13(outbreaks. Arch Intern Med 148):578–580
  73. Mann JM, Martin S, Hoffman R, Marrazzo S. Patient recovery from type A botulism (morbidity assessment following a large outbreak). Am J Public Health. 1981;71:266–269
  74. Martinez-Castrillo JC, Del Real MA, Hernandez Gonzalez A, et al.  Botulism with sensory symptoms (a second case). J Neurol Neurosurg Psychiatry. 1991;54:844–845[letter]
  75. McCarthy JD, Fleischmann J, George WL. Fever, dyspnea, and slurred speech following lower extremity trauma. Rev Infect Dis. 1991;13:172–176[clinical conference]
  76. McCroskey LM, Hatheway CL, Fenicia L, et al.  Characterization of an organism that produces type E botulinal toxin but which resembles Clostridium butyricum from the feces of an infant with type E botulism. J Clin Microbiol. 1986;23:201–202
  77. McCroskey LM, Hatheway CL, Woodruff BA, et al.  Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol. 1991;29:2618–2620
  78. Meng X, Karasawa T, Zou K, et al.  Characterization of a neurotoxigenic Clostridium butyricum strain isolated from the food implicated in an outbreak of food-borne type E botulism. J Clin Microbiol. 1997;35:2160–2162
  79. Merson MH, Dowell VR. Epidemiologic, clinical and laboratory aspects of wound botulism. N Engl J Med. 1973;289:1105–1110
  80. Middlebrook JL. Contributions of the US Army to botulinum toxin research. In:  Das Gupta B editors. Botulinum and Tetanus Neurotoxins and Biomedical Aspects. New York: Plenum Press; 1993;p. 515–519
  81. Middlebrook JL, Brown JE. Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Curr Top Microbiol Immunol. 1995;195:89–122
  82. Midura TF. Update (infant botulism). Clin Microbiol Rev. 1996;9:119–125
  83. Midura TF, Nygaard GS, Wood RM, Bodily HL. C. botulinum type F (isolation from venison jerky). Appl Microbiol. 1972;24:165–167
  84. Miller NR, Moses H. Ocular involvement in wound botulism. Arch Ophthalmol. 1977;95:1788–1789
  85. Monaco S, Freddi N, Francavilla E, et al.  Transient tonic pupils in botulism type B. J Neurol Sci. 1998;156:96–98
  86. Montecucco C, Schiavo G. Tetanus and botulism neurotoxins (a new group of zinc proteases). Trends Biochem Sci. 1993;18:324–327
  87. Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol. 1994;13:1–8
  88. Oh SJ. Botulism (electrophysiological studies). Ann Neurol. 1977;1:481–485
  89. Passaro DJ, Werner SB, McGee J. Wound botulism associated with black tar heroin among injecting drug users. JAMA. 1998;279:859–863
  90. Paterson DL, King MA, Boyle RS, et al.  Severe botulism after eating home-preserved asparagus. Med J Aust. 1992;157:269–270
  91. Pickett J, Berg B, Chaplin E, Brunstetter-Shafer MA. Syndrome of botulism in infancy (clinical and electrophysiologic study). N Engl J Med. 1976;295:770–772
  92. Pickett JB 3d . AAEE case report #16 (Botulism). Muscle Nerve. 1988;11:1201–1205
  93. Popoff MR. Ecology of neurotoxigenic strains of clostridia. Curr Top Microbiol Immunol. 1995;195:1–29
  94. Prevot AR, Terrasse J, Daumail J. Existence en France du botulisme humain de Type C. Bull Acad Natl Med Paris. 1955;139:355–358
  95. Rapoport S, Watkins PB. Descending paralysis resulting from occult wound botulism. Ann Neurol. 1984;16:359–361
  96. Roblot P, Roblot F, Fauchere JL, et al.  Retrospective study of 108 cases of botulism in Poitiers, France. J Med Microbiol. 1994;40:379–384
  97. Ruthman JC, Hendricksen DK, Bonefeld R. Emergency department presentation of type A botulism. Am J Emerg Med. 1985;3:203–205
  98. Sanders AB, Seifert S, Kobernick M. Botulism. J Fam Pract. 1983;16:987–988993–4, 999–1000,
  99. Schiavo G, Benfenati F, Poulain B, et al.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359:832–835[see comments]
  100. Schubart P, Kasperski S, Schroder P: [Eye involvement in botulism]. Klin Monatsbl Augenheilkd 187:142–3, 1985
  101. Scully RE. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 22-1997. A 58-year-old woman with multiple cranial neuropathies. N Engl J Med. 1997;337:184–190[clinical conference]
  102. Scully RE. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 48-1980. N Engl J Med. 1980;303:1347–1355
  103. Segal N, Cosma A: [Accomodation paralysis as an important sign in the diagnosis of botulism]. Rev Chir Oncol Radiol ORL Oftalmol Stomatol Ser Oftalmol 23:37–8, 1979
  104. Shapiro BE, Soto O, Shafqat S, Blumenfeld H. Adult botulism. Muscle Nerve. 1997;20:100–102[see comments]
  105. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response. A public health strategy for a global challenge. JAMA. 1997;278:433–435
  106. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the U.S. (a clinical and epidemiologic review). Ann Intern Med. 1998;129:221–228
  107. Shih Y, Chao SY. Botulism in China. Rev Infect Dis. 1986;8:984–990
  108. Shugar MA, Granich MS, Reardon EJ. The otolaryngologic presentation of botulism. Laryngoscope. 1981;91:121–124
  109. Simcock PR, Kelleher S, Dunne JA. Neuro-ophthalmic findings in botulism type B. Eye. 1994;8:646–648
  110. Simon JD. Biological terrorism. Preparing to meet the threat. JAMA. 1997;278:428–430
  111. Smith LD, Jackson EK, Graham RM. C. botulinum (characteristics and occurrence). Rev Infect Dis. 1979;1:637–641
  112. Sonnabend O, Sonnabend W, Heinzle R, et al.  Isolation of C. botulinum type G and identification of type G botulinal toxin in humans (report of five sudden unexpected deaths). J Infect Dis. 1981;143:22–27
  113. St. Louis ME, Peck SH, Bowering D, et al.  Botulism from chopped garlic (delayed recognition of a major outbreak). Ann Intern Med. 1988;108:363–368
  114. Stahl JS, Averbuch-Heller L, Remler BF, Leigh RJ. Clinical evidence of extraocular muscle fiber-type specificity of botulinum toxin. Neurology. 1998;51:1093–1099
  115. Tacket CO, Shandera WX, Mann JM, et al.  Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 1984;76:794–798
  116. Tagle P, Tapia J, Soza M, Court J: [Botulism: II. Neurological aspects of a mass poisoning]. Rev Med Chil 102:127–9, 1974
  117. Terranova W, Breman JG, Locey RP, Speck S. Botulism type B (epidemiologic aspects of an extensive outbreak). Am J Epidemiol. 1978;108:150–156
  118. Terranova W, Palumbo JN, Breman JG. Ocular findings in botulism type B. JAMA. 1979;241:475–477
  119. Thompson JA, Glasgow LA, Warpinski JR, Olson C. Infant botulism (clinical spectrum and epidemiology). Pediatrics. 1980;66:936–942
  120. Townes JM, Cieslak PR, Hatheway CL, et al.  An outbreak of type A botulism associated with a commercial cheese sauce. Ann Intern Med. 1996;125:558–563[see comments]
  121. van Ermengem E. Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Zeitschrift fur Hyg und Infektionskr-ankheiten. 1897;26:1–56
  122. Villar RG, Shapiro RL, Busto S, et al.  Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina. JAMA. 1999;281:1334–13381340,
  123. Vita G, Girlanda P, Puglisi RM, et al.  Cardiovascular-reflex testing and single-fiber electromyography in botulism. A longitudinal study. Arch Neurol. 1987;44:202–206
  124. Wapen BD, Gutmann L. Wound botulism. A case report. JAMA. 1974;227:1416–1417
  125. Weber JT, Hibbs RG, Darwish A, et al.  A massive outbreak of type E botulism associated with traditional salted fish in Cairo. J Infect Dis. 1993;167:451–454
  126. Whittaker RL, Gilbertson RB, Garrett AS. Botulism, type E. Ann Intern Med. 1964;61:448–454
  127. Wigginton JM, Thill P. Infant botulism. A review of the literature. Clin Pediatr (Phila). 1993;32:669–674
  128. Wilson R, Morris JG, Snyder JD, Feldman RA. Clinical characteristics of infant botulism in the U.S. (a study of the non-California cases). Pediatr Infect Dis. 1982;1:148–150
  129. Zilinskas RA. Iraq's biological weapons. The past as future?. JAMA. 1997;278:418–424

PII: S0039-6257(01)00227-2

Survey of Ophthalmology
Volume 46, Issue 1 , Pages 25-34 , July 2001

Article Tools